FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012128103> ?p ?o ?g. }

• W2012128103 endingPage "e105193" @default.
• W2012128103 startingPage "e105193" @default.
• W2012128103 abstract "To compare persistence with tumor necrosis factor alpha (TNF) antagonists among rheumatoid arthritis patients in British Columbia. Treatment persistence has been suggested as a proxy for real-world therapeutic benefit and harm of treatments for chronic non-curable diseases, including rheumatoid arthritis. We hypothesized that the different pharmacological characteristics of infliximab, adalimumab and etanercept cause statistically and clinically significant differences in persistence.We conducted a population-based cohort study using administrative health data from the Canadian province of British Columbia. The study cohort included rheumatoid arthritis patients who initiated the first course of a TNF antagonist between 2001 and 2008. Persistence was measured as the time between first dispensing to discontinuation. Drug discontinuation was defined as a drug-free interval of 180 days or switching to another TNF antagonist, anakinra, rituximab or abatacept. Persistence was estimated and compared using survival analysis.The study cohort included 2,923 patients, 63% treated with etanercept. Median persistence in years (95% confidence interval) with infliximab was 3.7 (2.9-4.9), with adalimumab 3.3 (2.6-4.1) and with etanercept 3.8 (3.3-4.3). Similar risk of discontinuation was observed for the three drugs: the hazard ratio (95% confidence interval) was 0.98 (0.85-1.13) comparing infliximab with etanercept, 0.95 (0.78-1.15) comparing infliximab with adalimumab and 1.04 (0.88-1.22) comparing adalimumab with etanercept.Similar persistence was observed with infliximab, adalimumab and etanercept in rheumatoid arthritis patients during the first 9 years of use. If treatment persistence is a good proxy for the therapeutic benefit and harm of these drugs, then this finding suggests that the three drugs share an overall similar benefit-harm profile in rheumatoid arthritis patients." @default.
• W2012128103 created "2016-06-24" @default.
• W2012128103 creator A5042574911 @default.
• W2012128103 creator A5051166300 @default.
• W2012128103 creator A5065904248 @default.
• W2012128103 creator A5073931268 @default.
• W2012128103 creator A5076716488 @default.
• W2012128103 creator A5077543903 @default.
• W2012128103 date "2014-08-20" @default.
• W2012128103 modified "2023-09-26" @default.
• W2012128103 title "Comparative Persistence of the TNF Antagonists in Rheumatoid Arthritis – A Population-Based Cohort Study" @default.
• W2012128103 cites W1558329586 @default.
• W2012128103 cites W1683627320 @default.
• W2012128103 cites W1874236485 @default.
• W2012128103 cites W1966439074 @default.
• W2012128103 cites W1966874995 @default.
• W2012128103 cites W1970375970 @default.
• W2012128103 cites W1977078113 @default.
• W2012128103 cites W1980464290 @default.
• W2012128103 cites W1997106678 @default.
• W2012128103 cites W1999713711 @default.
• W2012128103 cites W2000183493 @default.
• W2012128103 cites W2000445173 @default.
• W2012128103 cites W2002261472 @default.
• W2012128103 cites W2004084979 @default.
• W2012128103 cites W2009572244 @default.
• W2012128103 cites W2014709373 @default.
• W2012128103 cites W2015993259 @default.
• W2012128103 cites W2016814912 @default.
• W2012128103 cites W2017651570 @default.
• W2012128103 cites W2018600081 @default.
• W2012128103 cites W2019258224 @default.
• W2012128103 cites W2021153631 @default.
• W2012128103 cites W2022194132 @default.
• W2012128103 cites W2022205836 @default.
• W2012128103 cites W2029116114 @default.
• W2012128103 cites W2044708557 @default.
• W2012128103 cites W2052067610 @default.
• W2012128103 cites W2061326496 @default.
• W2012128103 cites W2061533312 @default.
• W2012128103 cites W2063033401 @default.
• W2012128103 cites W2064133813 @default.
• W2012128103 cites W2079590652 @default.
• W2012128103 cites W2085780540 @default.
• W2012128103 cites W2088684279 @default.
• W2012128103 cites W2098077764 @default.
• W2012128103 cites W2100736304 @default.
• W2012128103 cites W2101583195 @default.
• W2012128103 cites W2108271686 @default.
• W2012128103 cites W2109479417 @default.
• W2012128103 cites W2129202470 @default.
• W2012128103 cites W2134083368 @default.
• W2012128103 cites W2134714663 @default.
• W2012128103 cites W2148201023 @default.
• W2012128103 cites W2149223963 @default.
• W2012128103 cites W2161159725 @default.
• W2012128103 cites W2162274668 @default.
• W2012128103 doi "https://doi.org/10.1371/journal.pone.0105193" @default.
• W2012128103 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4139324" @default.
• W2012128103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25141123" @default.
• W2012128103 hasPublicationYear "2014" @default.
• W2012128103 type Work @default.
• W2012128103 sameAs 2012128103 @default.
• W2012128103 citedByCount "33" @default.
• W2012128103 countsByYear W20121281032015 @default.
• W2012128103 countsByYear W20121281032016 @default.
• W2012128103 countsByYear W20121281032018 @default.
• W2012128103 countsByYear W20121281032019 @default.
• W2012128103 countsByYear W20121281032020 @default.
• W2012128103 countsByYear W20121281032021 @default.
• W2012128103 countsByYear W20121281032022 @default.
• W2012128103 countsByYear W20121281032023 @default.
• W2012128103 crossrefType "journal-article" @default.
• W2012128103 hasAuthorship W2012128103A5042574911 @default.
• W2012128103 hasAuthorship W2012128103A5051166300 @default.
• W2012128103 hasAuthorship W2012128103A5065904248 @default.
• W2012128103 hasAuthorship W2012128103A5073931268 @default.
• W2012128103 hasAuthorship W2012128103A5076716488 @default.
• W2012128103 hasAuthorship W2012128103A5077543903 @default.
• W2012128103 hasBestOaLocation W20121281031 @default.
• W2012128103 hasConcept C126322002 @default.
• W2012128103 hasConcept C17991360 @default.
• W2012128103 hasConcept C207103383 @default.
• W2012128103 hasConcept C2777138892 @default.
• W2012128103 hasConcept C2777226972 @default.
• W2012128103 hasConcept C2777575956 @default.
• W2012128103 hasConcept C2778715236 @default.
• W2012128103 hasConcept C2780132546 @default.
• W2012128103 hasConcept C2908647359 @default.
• W2012128103 hasConcept C44249647 @default.
• W2012128103 hasConcept C71924100 @default.
• W2012128103 hasConcept C72563966 @default.
• W2012128103 hasConcept C99454951 @default.
• W2012128103 hasConceptScore W2012128103C126322002 @default.
• W2012128103 hasConceptScore W2012128103C17991360 @default.
• W2012128103 hasConceptScore W2012128103C207103383 @default.
• W2012128103 hasConceptScore W2012128103C2777138892 @default.
• W2012128103 hasConceptScore W2012128103C2777226972 @default.

• next